Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients

Thrombosis Research

Volumn 132, Issue 1, 2013, Pages 81-87

  Zhang, Lanning ^a   Chen, Yanming ^a   Jin, Ying ^a   Qu, Fei ^a   Li, Jiayue ^a   Ma, Cong ^a   Yang, Jie ^a   Xu, Bin ^a   Wang, Hongjuan ^a   Li, Xiaoqi ^a   Li, Yang ^a   Zhang, Yuxiao ^a   Lu, Caiyi ^a   Yin, Tong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

ABCB1; Clopidogrel; CYP2C19; Pharmacogenetics; Platelet reactivity; PON1

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARYLDIALKYLPHOSPHATASE 1; CLOPIDOGREL; CYTOCHROME P450 2C19; MULTIDRUG RESISTANCE PROTEIN 1;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CHINESE; DRUG ABSORPTION; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HIGH ON TREATMENT PLATELET REACTIVITY; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC ACTIVATION; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PREVALENCE; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; WILD TYPE;

ABCB1; CLOPIDOGREL; CYP2C19; PHARMACOGENETICS; PLATELET REACTIVITY; PON1;

ACUTE CORONARY SYNDROME; AGED; ARYL HYDROCARBON HYDROXYLASES; ARYLDIALKYLPHOSPHATASE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PLATELETS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TICLOPIDINE;

EID: 84881311995     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.05.006     Document Type: Article

References (47)

1. F.G. Kushner, M. Hand, S.C. Smith Jr., S.B. King III, J.L. Anderson, and E.M. Antman 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 54 2009 2205 2241
2. S.B. King III, S.C. Smith Jr., J.W. Hirshfeld Jr., A.K. Jacobs, D.A. Morrison, and D.O. Williams 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee Circulation 117 2008 261 295
3. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
4. P.A. Gurbel, R.C. Becker, K.G. Mann, S.R. Steinhubl, and A.D. Michelson Platelet function monitoring in patients with coronary artery disease J Am Coll Cardiol 50 2007 1822 1834 (Pubitemid 350007957)
5. L. Bonello, U.S. Tantry, R. Marcucci, R. Blindt, D.J. Angiolillo, and R. Becker Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
6. C.H. Pierce, J.M. Houle, J.P. Dickinson, M. Kindermans, E. Serre-Lacroix, and G. Kieffer Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers Semin Thromb Hemost 25 Suppl. 2 1999 35 39 (Pubitemid 29350290)
7. S.R. Steinhubl Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines Circulation 121 2010 481 483
8. O. Rideg, A. Komocsi, T. Magyarlaki, M. Tokes-Fuzesi, A. Miseta, and G.L. Kovacs Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention Pharmacogenomics 12 2011 1269 1280
9. P.A. Gurbel, and U.S. Tantry Clopidogrel resistance? Thromb Res 120 2007 311 321 (Pubitemid 46881255)
10. G. Hollopeter, H.M. Jantzen, D. Vincent, G. Li, L. England, and V. Ramakrishnan Identification of the platelet ADP receptor targeted by antithrombotic drugs Nature 409 2001 202 207 (Pubitemid 32144286)
11. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, A. Gandhi, K. Ryan, and R.B. Horenstein Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
12. G. Pare, S.R. Mehta, S. Yusuf, S.S. Anand, S.J. Connolly, and J. Hirsh Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N Engl J Med 363 2010 1704 1714
13. L. Wallentin, S. James, R.F. Storey, M. Armstrong, B.J. Barratt, and J. Horrow Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
14. M.J. Price, U.S. Tantry, and P.A. Gurbel The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors Rev Cardiovasc Med 12 2011 1 12
15. H.J. Bouman, E. Schomig, J.W. van Werkum, J. Velder, C.M. Hackeng, and C. Hirschhauser Paraoxonase-1 is a major determinant of clopidogrel efficacy Nat Med 17 2011 110 116
16. D. Sibbing, W. Koch, S. Massberg, R.A. Byrne, J. Mehilli, and S. Schulz No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting Eur Heart J 32 2011 1605 1613
17. P. Fontana, R. James, I. Barazer, P. Berdague, J.F. Schved, and M. Rebsamen Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study J Thromb Haemost 9 2011 1664 1666
18. D. Trenk, W. Hochholzer, M.F. Fromm, O. Zolk, C.M. Valina, and C. Stratz Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement Circ Cardiovasc Genet 4 2011 429 436
19. J.S. Hulot, J.P. Collet, G. Cayla, J. Silvain, F. Allanic, and A. Bellemain-Appaix CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients Circ Cardiovasc Interv 4 2011 422 428
20. D. Sibbing, W. Koch, D. Gebhard, T. Schuster, S. Braun, and J. Stegherr Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
21. D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, and A. Schomig Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
22. M. Man, M. Farmen, C. Dumaual, C.H. Teng, B. Moser, and S. Irie Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans J Clin Pharmacol 50 2010 929 940
23. J.M. Lee, S. Park, D.J. Shin, D. Choi, C.Y. Shim, and Y.G. Ko Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans Am J Cardiol 104 2009 46 51
24. J.A. Goldstein, T. Ishizaki, K. Chiba, S.M. de Morais, D. Bell, and P.M. Krahn Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations Pharmacogenetics 7 1997 59 64 (Pubitemid 27153320)
25. S.C. Sim, C. Risinger, M.L. Dahl, E. Aklillu, M. Christensen, and L. Bertilsson A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 2006 103 113 (Pubitemid 43069582)
26. X.F. Tang, J. Wang, J.H. Zhang, X.M. Meng, B. Xu, and S.B. Qiao Effect of the CYP2C19*2 and*3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention Eur J Clin Pharmacol 69 2013 1103 1112
27. E. Jacqz, H. Dulac, and H. Mathieu Phenotyping polymorphic drug metabolism in the French Caucasian population Eur J Clin Pharmacol 35 1988 167 171
28. T. Kubota, K. Chiba, and T. Ishizaki Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population Clin Pharmacol Ther 60 1996 661 666 (Pubitemid 27025913)
29. Y. Shu, and H.H. Zhou Individual and ethnic differences in CYP2C19 activity in Chinese populations Acta Pharmacol Sin 21 2000 193 199 (Pubitemid 30160975)
30. M.Y. Chan, K. Tan, H.C. Tan, P.T. Huan, B. Li, and Q.H. Phua CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects Pharmacogenomics 13 2012 533 542
31. H. Wu, J. Qian, J. Xu, A. Sun, W. Sun, and Q. Wang Besides CYP2C19, PON1 genetic variant influences post-clopidogrel platelet reactivity in Chinese patients Int J Cardiol 22 2012 887 890
32. S. Mohamed Ali, and S.E. Chia Interethnic variability of plasma paraoxonase (PON1) activity towards organophosphates and PON1 polymorphisms among Asian populations-a short review Ind Health 46 2008 309 317
33. F.G. Kushner, M. Hand, S.C. Smith Jr., S.B. King III, J.L. Anderson, and E.M. Antman 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 120 2009 2271 2306
34. S.B. King III 2009 update of the ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction and guidelines on percutaneous coronary intervention: what should we change in clinical practice? Pol Arch Med Wewn 120 2010 6 8
35. P.D. Patel, and R.R. Arora Practical implications of ACC/AHA 2007 guidelines for the management of unstable angina/non-ST elevation myocardial infarction Am J Ther 17 2010 e24 e40
36. P.A. Gurbel, K.P. Bliden, K. Guyer, P.W. Cho, K.A. Zaman, and R.P. Kreutz Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study J Am Coll Cardiol 46 2005 1820 1826 (Pubitemid 41579802)
37. S.J. Hwang, Y.H. Jeong, I.S. Kim, J.S. Koh, M.K. Kang, and Y. Park The cytochrome 2C19*2 and*3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention Thromb Res 127 2011 23 28
38. H.R. Luo, R.E. Poland, K.M. Lin, and Y.J. Wan Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study Clin Pharmacol Ther 80 2006 33 40 (Pubitemid 43946839)
39. Y.H. Jeong, U.S. Tantry, I.S. Kim, J.S. Koh, T.J. Kwon, and Y. Park Effect of CYP2C19*2 and*3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin Circ Cardiovasc Interv 4 2011 585 594
40. I.S. Kim, Y.H. Jeong, Y. Park, K.S. Park, S.E. Yun, and J.R. Park Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype JACC Cardiovasc Interv 4 2011 381 391
41. D.Y. Chen, C.Y. Wang, M.S. Wen, T.H. Lee, Y. Chu, and M.J. Hsieh Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population PLoS One 7 2012 e39178
42. J.L. Reny, C. Combescure, Y. Daali, and P. Fontana Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis J Thromb Haemost 10 2012 1242 1251
43. J. Jaitner, T. Morath, R.A. Byrne, S. Braun, D. Gebhard, and I. Bernlochner No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting Circ Cardiovasc Interv 5 82-8 2012 S1 S2
44. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, J.R. Walker, and T. Simon Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 376 2010 1312 1319
45. G. Campo, G. Parrinello, P. Ferraresi, B. Lunghi, M. Tebaldi, and M. Miccoli Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome J Am Coll Cardiol 57 2011 2474 2483
46. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Meneveau Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
47. P.A. Gurbel, and U.S. Tantry Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 125 2012 1276 1287 [discussion 87]